At Cellares, everything we do is driven by our mission: accelerating access to life-saving cell therapies.
Our Finance team combines traditional financial planning and analysis with business analytics and broader strategic decision support for both near-term execution and long-term planning. We aim to hire individuals with proven experience in finance and business strategy and a passion for continuous improvement in complementary data management, analytics, and data science disciplines.
This role will report to the VP of Finance, leading Corporate FP&A and partnering with our R&D, Commercialization, and G&A teams as we scale our rapidly growing business
Responsibilities
- Own the company’s consolidated financial model and associated material used for executive, board, and investor meetings; lead discussions on the strategic implications of pricing, gross margin, cash flow management, investment, and other resource allocation decisions
- Lead the company’s Operating Plan process: partner with executives to develop, commit to, and attain financial plans supported by comprehensive models of the key metrics and physical inputs that drive financial results
- Monitor key metrics and provide real-time analysis and insights on progress and variances to plans and lead in-depth strategic financial analysis and recommendations during quarterly reviews
- Identity and assess focus areas across the business to improve gross margin, profitability, and cash flow, propose initiatives supported by robust analysis, and partner with business leaders to execute and attain targets
- Drive strategic decisions through business cases and models evaluating various capital allocation decisions including but not limited to R&D investments, BOM cost reductions, insourcing versus outsourcing, product pricing, and headcount planning
Requirements
- Bachelor's and/or Master’s degree in Finance, Economics, Accounting, Engineering, or related; MBA preferred
- 10+ years of experience in highly analytical and results-oriented roles, including financial planning and analysis, management consulting, investment banking, or related
- Strong understanding of accounting, budgeting, forecasting, and business operations principles, processes, and systems
- Advanced financial modeling skills, including P&Ls, balance sheets, cash flow statements, and key performance indicators (KPIs)
- Experience managing and analyzing large datasets and ability to distill and present as clear and succinct executive-level insights
- Excellent problem-framing, problem-solving, and project management skills in a fast-paced, dynamic environment
- Experience in high-growth, technology-driven companies, ideally within the life sciences or healthcare industry
- Experience with advanced Excel BI functionality and languages (Power Query (M), PowerPivot (DAX)) and visualization tools like PowerBI or Tableau
- Proficiency in SQL and Python and experience with commercial and emerging analytics tools, technologies, and languages
Preferred
Top Skills
What We Do
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope.
Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.
Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need.
The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
